Skip to content
StockMarketAgent
Direct answer
Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow. Fair value range: low $109, high $170, with mid-point at $140.
Stock analysis

ZTS fair value $109–$170

By StockMarketAgent.AI team· supervised by
Đã phân tích: 2026-05-12Cập nhật tiếp theo: 2026-08-12Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
Giá
$76.94
▲ +62.83 (+81.66%)
Giá trị hợp lý
$140
$109–$170
Khuyến nghị
Mua mạnh
confidence 88/100
Tiềm năng tăng
+81.7%
upside to fair value
Biên an toàn
$118.80
MoS level · 15%
Vốn hóa thị trường
$32.3B
P/E fwd 10.3
Dự phòng tiếng AnhVI
Hiển thị bản gốc tiếng Anh trong khi đang dịch
Báo cáo này chưa được dịch. Hãy làm mới sau vài phút khi hàng đợi dịch xử lý xong.

§1 Tóm tắt điều hành

  • Composite fair value $140 with high case $170.
  • Implied upside of 81.7% to fair value.
  • Moat 9/10 · confidence 88/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$140
Margin of safety
+45.0%
Confidence
88/100
Moat
9/10

Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.

$76.94Price
Low $109.15
Mid $139.77
High $170.49

Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow.

  • Intangible assets via unmatched patent
    Intangible assets via unmatched patent portfolio and brand loyalty.
  • High switching costs for veterinary
    High switching costs for veterinary practitioners integrated into the Zoetis ecosystem.
  • Cycle upside
    Accelerating pet humanization driving inelastic, premium companion animal healthcare spending.

§2 Kịch bản tiêu cực

A macroeconomic shock compressing discretionary pet spending combined with a cyclical livestock downturn would threaten historical 37% operating margins. The reverse DCFReverse DCFInverts a standard DCF: instead of solving for fair value, we solve for the growth rate the current price already implies — a useful test of whether the market's assumptions are reasonable. implies the market is already pricing in a structural decay (-2.52% perpetual growth), providing a massive margin of safetyMargin of safetyThe discount required between fair value and current price before we recommend buying. Typically 15% for wide-moat names, 25–35% for cyclicals or low-confidence cases. against such cyclical shocks.

Các cách luận điểm này có thể đổ vỡ

Margin Contraction

· Low

Operating margins sustainably drop below 35% due to generic competition and loss of pricing power.

FV impact
Valuation compresses to the $109.15 low-end threshold.

Livestock Headwinds

· Medium

Prolonged livestock disease cycle reduces the agricultural segment revenues structurally, dragging corporate growth.

FV impact
Mild drag on terminal value generation and forward EPS.

Macro Demand Shock

· Medium

Deep recession forces broad reduction in discretionary companion animal treatments and veterinary visits.

FV impact
Near-term EPS shock testing the $110 forward earnings scenario value.
Tín hiệu cảnh báo sớm cần theo dõi
Chỉ sốHiện tạiNgưỡng kích hoạt
Operating margin contracting below 35% over two consecutive quarters.MonitorDeterioration versus the report thesis
Forward EPS growth turning negative.MonitorDeterioration versus the report thesis
ROIC dropping precipitously toward the 8.43% WACC.MonitorDeterioration versus the report thesis
Erosion of the 71.8% gross margin floor.MonitorDeterioration versus the report thesis
Accelerated generic approvals targeting core parasiticide or dermatology portfolios.MonitorDeterioration versus the report thesis

§3 Lịch sử tài chính

Báo cáo kết quả kinh doanh — sáu kỳ gần nhất

Khoản mục2022-12-312023-12-312024-12-312025-12-31Trend
Doanh thu$8.08B$8.54B+5.7%$9.26B+8.4%$9.47B+2.3%+5.4%
Lợi nhuận gộp$5.63B$5.98B$6.54B$6.80B+6.5%
Lợi nhuận hoạt động$2.93B$3.07B$3.39B$3.60B+7.1%
Lợi nhuận ròng$2.11B$2.34B+10.9%$2.49B+6.4%$2.67B+7.2%+8.1%
EPS (pha loãng)$4.49$5.07$5.47$6.02+10.3%
EBITDA$3.34B$3.67B$3.86B$4.07B+6.8%
R&D$539.0M$614.0M$686.0M$698.0M+9.0%
SG&A$2.01B$2.15B$2.32B$2.38B+5.8%

Điểm chất lượng

OCF / Lợi nhuận ròng
1.09×
>1 cho thấy chất lượng lợi nhuận cao
Cổng chất lượng kế toán
Fail
Cổng điều chỉnh theo ngành
ROIC
22.5%
Tỷ suất sinh lời trên vốn đầu tư
Người đăng ký cá nhân — từ §411 phần nữa

Đọc phân tích đầy đủ — 11 phần nữa.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Báo cáo đầy đủ cho mọi mã được phủ
Lưu trữ khuyến nghị 24 tháng
Bản tin watchlist + cảnh báo thay đổi khuyến nghị
Xuất PDF + DOCX bằng mọi ngôn ngữ
Bắt đầu dùng thử miễn phí
Hủy bất kỳ lúc nào.
REVERSE DCF FAQ

ZTS reverse dcf questions

  1. Reverse DCF for ZTS (ZTS) backs out the revenue or earnings growth rate the current share price implies, holding terminal value, margin, and discount-rate assumptions constant.
FAQ

ZTS — frequently asked questions

  1. Based on our latest analysis, ZTS looks meaningfully undervalued. The current price is $76.9 versus a composite fair-value midpoint of $140 (range $109–$170), which implies roughly 81.7% upside to the midpoint.
Related coverage

Names readers of ZTS also follow

Same archetype: mature-compounder